UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract…
Pharmaceuticals, Biotechnology and Life Sciences
Recent Data Presentation Highlights Consistent Complete Response Rate and Strong Durability at Six-Months in Evaluable Patients with Low-Grade Upper Tract…
Spending on all U.S. medicines increased 4.5 percent to $344 billion on a net price basis, despite lower price growth,…
– Data from FIERCE-22 Phase 2 Trial in Metastatic Bladder Cancer – SAN LEANDRO, Calif.–(BUSINESS WIRE)–Rainier Therapeutics, Inc., a privately-held…
BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration with the LuMind IDSC Foundation (LuMind IDSC) involving use of Cerveau’s…
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura, senior vice president, investor relations, has been named a…
Net Product Revenue for Auryxia Increases to $23.1 Million for Q1’FY19, Up 12.1% from Q1’FY18; Full Enrollment of Phase 3…
DUBLIN–(BUSINESS WIRE)–The “Global Laryngeal Cancer Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The laryngeal cancer therapeutics market…
— Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of…
Alpine transitions to clinical-stage company Completed financing to fund further development of both lead programs SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc.…
An additional treatment modality would provide more flexibility in how patients receive vedolizumab, a biologic with a gut-selective mode of…